News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
280,000 Results
Type
Article (14559)
Company Profile (57)
Press Release (265382)
Multimedia
Podcasts (74)
Webinars (13)
Section
Business (101344)
Career Advice (468)
Deals (15482)
Drug Delivery (86)
Drug Development (36915)
Employer Resources (50)
FDA (6441)
Job Trends (6263)
News (151256)
Policy (14191)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (458)
Accelerated approval (27)
ADA (11)
Adcomms (9)
Allergies (105)
Alliances (23374)
ALS (76)
Alzheimer's disease (554)
Antibody-drug conjugate (ADC) (187)
Approvals (6804)
Artificial intelligence (302)
ASCO (113)
Autoimmune disease (87)
Automation (22)
Bankruptcy (152)
Best Places to Work (4383)
BIO (24)
BIOSECURE Act (9)
Biosimilars (171)
BioSpace Insights (66)
Biotechnology (27)
Bladder cancer (55)
Brain cancer (41)
Breast cancer (221)
Cancer (1845)
Cardiovascular disease (213)
Career advice (423)
Career pathing (15)
CAR-T (69)
CDC (8)
Cell therapy (209)
Cervical cancer (20)
Clinical research (32878)
Collaboration (1032)
Commercialization (3)
Company closure (2)
Compensation (434)
Complete response letters (51)
COVID-19 (790)
CRISPR (56)
C-suite (719)
Cystic fibrosis (65)
Data (2714)
Decentralized trials (1)
Denatured (19)
Depression (63)
Dermatology (17)
Diabetes (172)
Diagnostics (1495)
Digital health (17)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (189)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (109)
Earnings (34626)
Editorial (25)
Employer branding (4)
Employer resources (46)
Events (40124)
Executive appointments (651)
FDA (7979)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (597)
Gene editing (90)
Generative AI (32)
Gene therapy (210)
GLP-1 (501)
Government (1440)
Grass and pollen (4)
Guidances (177)
Healthcare (3652)
Hematology (66)
HIV (21)
Huntington's disease (13)
IgA nephropathy (61)
Immunology and inflammation (94)
Immuno-oncology (34)
Indications (110)
Infectious disease (892)
Inflammatory bowel disease (89)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (152)
Interviews (59)
IPO (5946)
IRA (33)
Job creations (2061)
Job search strategy (375)
JPM (29)
Kidney cancer (15)
Labor market (39)
Layoffs (216)
Leadership (11)
Legal (3456)
Licensing (6)
Liver cancer (27)
Longevity (11)
Lung cancer (258)
Lymphoma (168)
Machine learning (16)
Management (17)
Manufacturing (631)
Marketing (7)
MASH (93)
Medical affairs (1)
Medical device (1322)
Medtech (1344)
Mergers & acquisitions (10109)
Metabolic disorders (590)
mRNA (66)
Multiple sclerosis (66)
NASH (15)
Neurodegenerative disease (126)
Neuropsychiatric disorders (51)
Neuroscience (1134)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (611)
Now hiring (24)
Obesity (304)
Opinion (154)
Ovarian cancer (69)
Pain (141)
Pancreatic cancer (78)
Parkinson's disease (118)
Partnered (12)
Patents (306)
Patient recruitment (208)
Peanut (15)
People (30435)
Pharmaceutical (33)
Pharmacy benefit managers (19)
Phase 1 (8521)
Phase 2 (13866)
Phase 3 (12550)
Pipeline (4066)
Policy (153)
Postmarket research (1407)
Preclinical (3432)
Press Release (25)
Prostate cancer (123)
Psychedelics (27)
Radiopharmaceuticals (168)
Rare diseases (523)
Real estate (2668)
Recruiting (19)
Regulatory (11640)
Reports (19)
Research institute (583)
Resumes & cover letters (55)
Rett syndrome (12)
RNA editing (9)
RSV (26)
Schizophrenia (89)
Series A (119)
Series B (69)
Service/supplier (1)
Sickle cell disease (62)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1656)
State (2)
Stomach cancer (6)
Supply chain (69)
Tariffs (71)
The Weekly (53)
Vaccines (287)
Venture capital (44)
Weight loss (175)
Women's health (53)
Worklife (4)
Date
Last 7 days (236)
Last 30 days (844)
Last 365 days (10462)
2026 (6733)
2025 (10752)
2024 (12504)
2023 (14282)
2022 (19595)
2021 (20092)
2020 (19043)
2019 (14886)
2018 (11713)
2017 (13897)
2016 (13129)
2015 (15488)
2014 (12443)
2013 (10610)
2012 (11414)
2011 (11963)
2010 (10932)
Location
Africa (325)
Alabama (23)
Alaska (1)
Arizona (95)
Arkansas (4)
Asia (21394)
Australia (2761)
California (4207)
Canada (1907)
China (813)
Colorado (184)
Connecticut (170)
Delaware (177)
Europe (42286)
Florida (806)
Georgia (81)
Hawaii (2)
Idaho (11)
Illinois (487)
India (82)
Indiana (331)
Iowa (2)
Japan (380)
Kansas (89)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (531)
Massachusetts (3393)
Michigan (55)
Minnesota (219)
Mississippi (1)
Missouri (41)
Montana (9)
Nebraska (8)
Nevada (20)
New Hampshire (9)
New Jersey (1856)
New Mexico (7)
New York (1202)
North Carolina (782)
North Dakota (2)
Northern California (1996)
Ohio (98)
Oklahoma (5)
Oregon (16)
Pennsylvania (907)
Puerto Rico (18)
Rhode Island (18)
South America (510)
South Carolina (12)
Southern California (1878)
Tennessee (78)
Texas (589)
United States (16621)
Utah (69)
Vermont (1)
Virginia (219)
Washington D.C. (42)
Washington State (307)
West Virginia (1)
Wisconsin (60)
Wyoming (1)
280,000 Results for "scilex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
June 12, 2026
·
7 min read
Press Releases
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
June 4, 2026
·
7 min read
Press Releases
Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
May 24, 2026
·
8 min read
Press Releases
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
July 7, 2026
·
8 min read
Press Releases
Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
July 6, 2026
·
9 min read
Press Releases
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
May 5, 2026
·
8 min read
Press Releases
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
September 23, 2025
·
9 min read
Press Releases
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
October 2, 2025
·
7 min read
Press Releases
Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
April 20, 2026
·
9 min read
Press Releases
Scilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
February 1, 2026
·
8 min read
1 of 28,000
Next
